CTR20191224: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of DX126-262 in Patients With Her2-Positive Advanced Breast and/or Gastric Cancer |
|
|
| Ongoing | 1 | 57 | China | DX126-262 - Hangzhou DAC Biotech | Hangzhou Duoxi Biotechnology Co., Ltd | HER2-positive advanced breast and/or gastric cancer | | | | |
